member
Benjamin Larimer, PhD
Co-founder and Chief Executive Officer

Benjamin Larimer, PhD

Co-founder and Chief Executive Officer

Education

MD Weill Cornell Medical College 1996

Industry Associations & Roles

Harvard Medical School

Clinical Interests

Lorem ipsum dolor sit amet consectetur. Ipsum metus sed scelerisque velit morbi mi in nibh. Nunc cursus sed facilisi sem viverra sit elementum. Non in elit a id sed at. Tortor venenatis varius facilisis eleifend vestibulum. Sapien pellentesque integer.

Bio

Dr. Larimer is a scientist entrepreneur and President and Chief Executive Officer of Cytosite Biopharma. Dr. Larimer was a co-discover of the lead Cytosite technology and guided it through successful first-in-human clinical trials. He also oversaw the developmental chemistry program of Cytosite, resulting in two additional clinical molecules. In 2023, Dr. Larimer was named to the Chief Executive Officer position to guide the commercialization of the granzyme B PET imaging program.

Ben holds a PhD in Biochemistry from the University of Missouri, and did his postdoctoral training at Massachusetts General Hospital in the lab of Dr. Mahmood. Following his fellowship, he began his own academic research lab at the University of Alabama Birmingham. He has been recognized for his scientific achievements through the NIH Directors’ New Innovator Award, Hal O’Brien Rising Star Award, and named One to Watch by the Society of Nuclear Medicine.

Recent Content from Benjamin

Publication

Cancer Research: Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response

May 1, 2017
Author: Michele
Reviewed by: Umar
Radiodiagnostic
External

Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response

May 1, 2017
Author: Michele
Reviewed by: Umar
Radiodiagnostic
External

The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging

October 16, 2018
Author: Michele
Reviewed by: Umar